Breaking News

Twitter TWTR Stock News

Twitter Inc (NYSE: TWTR)

Twitter is having a strong day in the market today. In the beginning of the day, it started off on highs, fell near the red line, and now, it’s spiking again. Today, we’ll talk about what we’re seeing from the stock now, why, and what to expect from TWTR ahead.

Trade smarter and make more money with Tradespoon!

What We’re Seeing From TWTR

As mentioned above, Twitter started the day off strong on earnings. However, throughout morning trading, the stock fell to the red line. Nonetheless, minutes ago, we started to see big gains again. The gains are likely attributed to news surrounding the Vine Mobile App, but we’ll get to that later. Currently (12:18), TWTR is trading at $17.51 per share after a gain of $0.22 per share (1.27%) thus far today.

Why We’re Seeing The Gains In The Stock

In early morning hours, TWTR released its earnings report, beating expectations in a big way with regard to both earnings and revenue. This led to the early morning pop. However, with the idea that user growth is still incredibly modest, we watched as the gains fell off throughout the morning. Nonetheless, the stock is headed up again.

The spike that happened minutes ago happened as Twitter made a big announcement with regard to the Vine Mobile App. The company said that it would be discontinuing the service. This comes after the company announced layoffs of about 9% of its workforce along with earnings. So, the restructuring plans are starting to come together and investors seem to like what they see.

What We Can Expect Ahead

While the future is starting to brighten up a bit for TWTR, there are still tons of unanswered questions. Revenue and earnings were strong, that’s great, but the company needs to get user growth in order. To their credit, user growth is starting to see an upward trend. However, at this rate, it would take years to appease investors. So, while TWTR seems to be heading in the right direction, there are still quite a few hurdles in the way.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required



[Image Courtesy of Pixabay]

CBS Corporation CBS Stock News

CBS Corporation Common Stock (NYSE: CBS)

CBS Corporation was off to a relatively normal start in the market today. That is, until about an hour into trading. Minutes ago, the stock started to skyrocket in a big way. We think we’ve uncovered the reason. Today, we’ll talk about what we’re seeing from the stock, why we’re seeing the movement, and what we can expect to see from CBS ahead.

Trade smarter and make more money with Tradespoon!

What We’re Seeing From CBS

As mentioned above, CBS was off to a normal start to the day in the early morning hours. However, that has changed, as the stock has found its way from the red to the green over the past few minutes. Currently (10:32), the stock is trading at $56.99 per share after a gain of $0.21 per share (0.37%) thus far today.

Why The Stock Is Gaining

While CBS hasn’t released any fundamental news with regard to the company, there is a big story going around. At the moment, the CNA Finance team is seeing quite a bit of chatter in social media about a possible takeover. According to the rumors, Comcast (CMCSA) is interested in acquiring CBS. The rumors do not include a per-stock price for the possible transaction.

What We Can Expect To See Ahead

First and foremost, it’s important to remember that the movement is being caused by rumors. There is no confirmation on either side of the coin that Comcast is indeed interested in acquiring CBS. With that said, the concept of the acquisition makes sense, and, if it happens, the stock is going to soar. So, keep a close eye on the story as it unfolds and make sure to subscribe below for updates!

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real time, actionable news delivered directly to your inbox? Join the CNA Finance mailing list below today!

Subscribe Today!

* indicates required



[Image Courtesy of Wikipedia]

0 723
Adaptimmune Therapeutics ADAP Stock News

Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP)

While Adaptimmune Therapeutics is currently taking a dive, the stock is likely to have a strong day in the market throughout the day. Just minutes ago, in the midst of the declines, the company made a key announcement surrounding a collaboration. Today, we’ll talk about the collaboration, what we’re seeing in the market, and what we can expect to see from ADAP ahead.

Trade smarter and make more money with Tradespoon!

ADAP Enters Into A Collaboration Agreement With Merck & Co.

As mentioned above, just minutes ago, Adaptimmune Therapeutics announced a new collaboration agreement. The agreement was signed with Merck & Co., also known as MSD outside of the US and Canada. The agreement surrounds the assessment of NY-ESO SPEAR T-cell therapy from ADAP in combination with KEYTRUDA, MSD’s anti-grogrammed death-1 inhibitor. The combination treatment is designed for patients dealing with multiple myeloma. In a statement, Rafael Amado, CMO at ADAP, had the following to offer:

In initial single-agent studies of our NY-SEO SPEAR T-cell therapy in patients with advanced myeloma in the context of stem cell transplantation, we have seen encouraging evidence of antitumor effect, safe administration and prolonged persistence of transduced cells… KEYTRUDA has shown preliminary evidence of activity in multiple myeloma, and there is preclinical evidence to support the view that the combination of NY-ESO SPEAR T-cell therapy and anti-PD1 therapy may lead to meaningful anti-tumor activity. We look forward to evaluating our therapy alone and in combination with KEYTRUDA in a randomized trial of patients with multiple myeloma whoa re refractory or have relapsed with standard therapy.”

What We’re Seeing From The Stock

While the news that was released today is overwhelmingly positive, Adaptimmune Therapeutics simply isn’t having the best of days in the market. Unfortunately, the stock has seen steady declines after strong pre-market growth. Currently (10:17), ADAP is trading at $4.84 per share after a loss of $0.07 per share, or 1.43%.

What We Can Expect To See Ahead

Moving forward, I’m expecting to see quite a bit of positivity out of ADAP stock. First and foremost, when investors start to see the PR, I’m expecting to see excitement leading to gains that could happen as soon as today. Additionally, in the long run, my opinion is still very bullish. At the end of the day, Adaptimmune is doing great things with the NY-ESO SPEAR T-cell therapy, and the fact that Merck is now collaborating with them further validates their efforts. All in all, I’m expecting to see gains in ADAP ahead.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real-time, actionable news delivered directly to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required



[Image Courtesy of Wikipedia]

0 4355
Acacia Communications ACIA Stock News

Acacia Communications, Inc. (NASDAQ: ACIA)

Right out of the gate this morning, Acacia Communications has had a rough time in the market. While there hasn’t been any fundamental news released surrounding the stock specifically, there is a good reason for the decline. Today, we’ll talk about what we’re seeing from the stock, why, and what we can expect to see from ACIA ahead. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

ACIA Is Having A Rough Day

As mentioned above, Acacia Communications is having an incredibly rough start to the trading session. As soon as the gate opened, the stock started to fall, and the declines are continuing at the moment. Currently (9:50), ACIA is trading at $80.85 per share after a loss of $6.68 per share, or 7.63%.

Why The Stock Is Falling

While the company hasn’t released any fundamental news today, there is a good reason for the declines. These declines are the result of news from one of the biggest clients that ACIA has. That client is ZTE. Before the bell, ZTE reported its earnings. Unfortunately, the company missed sales expectations. Because Acacia Communications is one of the larger suppliers to ZTE, the company is also feeling the pain associated with the poor sales numbers.

What We Can Expect To See Next

Moving forward, I have a relatively mixed opinion of what we can expect to see. First and foremost, ACIA is going to deal with the pain of its largest customer. That’s simply how business works. In the short term, investor concern will likely keep the stock down.

However, in the long term, my view is still relatively bullish. At the end of the day, the company has done an incredible job coming up with great products and turning them into profits. While the ZTE news may hurt for a while, ACIA is likely to be just fine in the long run.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real-time, actionable news delivered directly to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required



[Image Courtesy of Pixabay]

0 1174
Dr Pepper Snapple Group DPS Stock News

Dr Pepper Snapple Group Inc. (NYSE: DPS)

Dr Pepper Snapple Group was off to a relatively normal start in the market today. However, minutes ago, the CNA Finance team picked up a spike. After a bit of looking around, we found the reason. Below, we’ll talk about what we’re seeing from the stock, why, and what’s next surrounding DPS.

Trade smarter and make more money with Tradespoon!

DPS Spikes

As mentioned above, Dr Pepper Snapple Group was off to a relatively normal start. While the stock was in the green, the gains weren’t very large at all. However, minutes ago, we noticed that the stock is spiking. Currently (1:39), DPS stock is trading at $89.35 per share after a gain of $1.03 per share (1.17%) thus far today.

Why The Stock Is Spiking

As soon as we noticed the gains, the CNA Finance team started looking for the cause, and we’ve found it. While there has been no fundamental news released by the company, there is quite a bit of chatter surrounding DPS on social media.

According to the chatter, Dr Pepper Snapple Group is looking into acquiring more assets. In fact, it is suggested that the company will likely acquire BAI Brands. Of course, if that does happen, the acquisition will lead to a stronger product line for DPS over time.

What To Expect Ahead

First and foremost, I’d like to say that, regardless of how this news turns out, we’re likely to see long-run gains in DPS. However, in the short run, we’re likely to see some volatility, and the movement will largely be dictated by this story. If news breaks that Dr Pepper Snapple Group has purchased BAI Brands, we can expect to see more gains in the short. However, if this acquisition doesn’t happen, look for a correction in DPS.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Are you looking for real-time, actionable market news? Stop looking! Get the news delivered directly to your inbox by subscribing to the CNA Finance mailing list below!

Subscribe Today!

* indicates required



[Image Courtesy of Flickr]

0 2067
Lululemon Athletica LULU Stock News

Lululemon Athletica inc. (NASDAQ: LULU)

Lululemon Athletica is having an overwhelmingly strong day in the market today. While it was off to a relatively normal start, we noticed big gains starting just minutes ago. Today, we’ll talk about the gains we’re seeing, why we’re seeing the gains, and what we can expect to see from LULU stock ahead.

Trade smarter and make more money with Tradespoon!

What We’re Seeing From LULU

As mentioned above, Lululemon Athletica was off to a relatively normal start in the market today. However, in the past few minutes, things have changed in a big way. At the moment, the stock is skyrocketing. Currently (11:01), LULU is trading at $57.20 per share after a gain of $2.09 per share (3.79%) thus far today.

Why We’re Seeing The Gains

The gains that we’re seeing on LULU stock are happening for a very good reason. There is quite a bit of chatter surrounding a possible takeover. In fact, that chatter is that the CEO of the company may take it private. The rumors also give a possible price for the acquisition. In fact, it is being suggested that Lululemon athletica may be purchased for between $66 and $69 per share.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively mixed opinion of what we can expect to see. While I never suggest feeding into rumors, this one may actually have something to it. At the end of the day, movement in LULU stock in the short term will likely be largely dictated by news surrounding this story.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real-time, actionable market news delivered to your inbox? Subscribe to our mailing list below!

Subscribe Today!

* indicates required



[Image Courtesy of Wikimedia]

0 1891
Sarepta Therapeutics Inc SRPT Stock News

Sarepta Therapeutics Inc (NASDAQ: SRPT)

Sarepta Therapeutics is off to a rough start to the trading day today. However, I believe that this is likely to change, and in a big way. The reason? The company received a coverage letter from Humana. Today, we’ll talk about the letter, what we’re seeing from the stock, and what we can expect to see from SRPT ahead.

Trade smarter and make more money with Tradespoon!

SRPT Announces Receipt Of Coverage Letter

As mentioned above, Sarepta Therapeutics investors have a reason to be excited today. The company released a letter it received from Humana with regard to Exondys 51 (eteplirsen). Through the letter, SRPT informed investors that Humana will cover Exondys as long as specific conditions are met. To read the complete letter, click here.

What We’re Seeing From The Stock

While the announcement that Humana will be covering Exondys is overwhelmingly positive news, either investors haven’t seen the letter yet, or they are worried about the conditions. Nonetheless, the stock is taking a dive at the moment. Currently (10:09), SRPT is trading at $45.06 per share after a loss of $1.27 per share, or 2.74%.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from SRPT. The fact that Humana will be covering Exondys is overwhelmingly positive news. While I understand that there are conditions to the coverage, and that’s concerning to some investors, it’s important to remember the facts here. The truth is that Sarepta Therapeutics is benefiting from accelerated approval at the moment.

However, there is a final approval that needs to be achieved. The fact that Humana has decided to cover the treatment before final approval is overwhelmingly positive news. I would imagine that coverage will expand upon final approval. Not to mention, Humana does their research. Considering the fact that they have already released a coverage letter, chances are even greater that SRPT will indeed achieve final approval. All in all, I’m expecting gains ahead.

UPDATE: CNA Finance Chief Strategic Analyst, Kenny Soulstring, has weighed in on SRPT. To read his analysis, click here!

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real-time, actionable stock market news delivered directly to your inbox? Subscribe to the CNA Finance mailing list below!

Subscribe Today!

* indicates required



0 1031
OncoGenex Pharmaceuticals Inc OGXI Stock News

OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI)

OncoGenex Pharmaceuticals is having an incredible day in the market today, and for good reason. The company released results from a pivotal Phase 2 trial. Today, we’ll talk about the data that was released, how the stock reacted to the news, and what we can expect to see from OGXI ahead.

Trade smarter and make more money with Tradespoon!

OGXI Reports Positive Phase 2 Data

As mentioned above, OncoGenex Pharmaceuticals is having an incredibly strong day in the market today after releasing strong Phase 2 clinical data. The data came from the Borealis-2 trial of apatorsen in combination with docetaxel. The treatment was given to patients with metastatic bladder cancer whose disease had progressed following platinum-based chemotherapy.

According to the data that was released by OGXI, patients treated with apatorsen experienced a 20% reduction in risk of death, which is statistically significant. This result was compared to patients who were treated with docetaxel alone.

In terms of safety, the company also had relatively positive results to share. According to the data released by OGXI, the results show that safety results in patients treated with apatorsen and docetaxel were similar to those observed in patients treated with docetaxel alone. In a statement, Scott Cormack, President and CEO at OncoGenex, had the following to offer:

We are encouraged by these data that further support Hsp27 as a therapeutic target and add an additional level of evidence to previously completed trials of apatorsen in patients with bladder cancer… We look forward to completing the full data analysis from Borealis-2 and considering these data in our continuing work with MTS Health Partners in the exploration of strategic alternatives as announced in mid-August.”

How The Stock Is Reacting To The News

As investors, we know that the news moves the market, and, in this case, the news was overwhelmingly positive. As a result, we’re seeing incredibly strong gains in the value of OGXI shares. Currently (9:38), the stock is trading at $0.60 per share after a gain of $0.23 per share (61.38%) thus far today.

What We Can Expect To See Ahead

Moving forward, I have a relatively bullish opinion of what we can expect to see from OncoGenex Pharmaceuticals. At the end of the day, the Phase 2 data that was recently released was overwhelmingly positive. While the company does have some financial struggles as most companies in this phase of development do, it seems as though they are making all of the right moves and may be innovating something incredible here. All in all, I’m expecting to see gains in OGXI ahead.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real time, actionable stock market news delivered to your inbox as it happens? Subscribe to the CNA Finance mailing list below! (Free for a limited time only!)

Subscribe Today!

* indicates required



[Image Courtesy of Wikipedia]

0 1492
Dynavax Technologies Corporation DVAX Stock News

Dynavax Technologies Corporation (NASDAQ: DVAX)

Dynavax is having an incredibly strong start to the day today, and for good reason. The company released a PR informing investors of details with regard to a Phase 3 clinical trial. Today, we’ll talk about the trial, what we’re seeing in the market, and what we can expect to see from DVAX ahead.

Trade smarter and make more money with Tradespoon!

DVAX Releases Key Data

As mentioned above, Dynavax Technologies released important data today. The data was a result of a sub-group in a Phase 3 trial of HEPLISAV-B. The sub-group the data surrounded was the HBV-23 group.

In the data released by DVAX, we learned that when the treatment was provided as two doses over the course of a month, significantly higher seroprotection rates were induced than in the approved hepatitis B vaccine Engerix-B when administered as three doses over six months.

In a statement, Rob Janssen, M.D., CMO at DVAX, had the following to offer:

Hepatitis B remains an important health problem in the United States with approximately 20,000 new infections in adults every year. Although hepatitis B vaccines have been available for 25 years and served an important role in preventing the disease, approved hepatitis B vaccines have several limitations, including lower protection rates in some populations… We were encouraged to see that HEPLISAV-B administered as two doses over one month provided a significantly higher rate of seroprotection in these individuals than the existing hepatitis B vaccine. The lower immunology observed in sub-groups in the Engerix-B arm of this Phase 3 study demonstrates the clinical need for a hepatitis B vaccine that can provide higher rates of seroprotection with fewer doses to adequately protect adults against the consequences of this chronic viral infection.”

How The Stock Reacted To The News

As we know, the news moves the market. In the case of Dynavax Technologies, the news was overwhelmingly positive. So naturally, a positive reaction is being seen. Currently (in pre-market trading), DVAX is trading at $10.75 per share after a gain of 5.91%.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from Dynavax Technologies. At the end of the day, the company is doing incredible things with HEPLISAV-B and, as positive data continues to be released surrounding the vaccine, we’re likely to see more and more gains. At the end of the day, based on the results released thus far, I’m expecting the vaccine to be approved, leading to a strong line of revenue and a high chance of profits.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real time, actionable stock market news delivered to your inbox as it happens? Join our mailing list below! (Free for a limited time only.)

Subscribe Today!

* indicates required



[Image Courtesy of Flickr]

0 1041
Concordia International CXRX Stock News

Concordia International Corp (NASDAQ: CXRX)

Concordia International started the day off like any other day in the market. However, minutes ago, the CNA Finance team noticed something strange. From there, the stock started to tank. Nonetheless, we believe we’ve dug up the reason. Here’s what’s happening, why it’s happening, and what we can expect to see from CXRX moving forward.

Trade smarter and make more money with Tradespoon!

CXRX Takes A Dive

As mentioned above, Concrodia International was off to a relatively normal start in the market today. That is until just a few minutes ago when the stock started to take a dive. Falling from the green to the red in minutes, CXRX is currently (11:13) trading at $4.03 per share after a loss of $0.20 per share or 4.73%.

Why We’re Seeing The Declines

These are big declines, but what exactly is going on? As soon as the trend started, the CNA Finance team went digging, and it didn’t take long to dig something up. According to Twitter chatter, Concordia International is now under investigation. Unfortunately, there hasn’t been any news with regard to why CXRX is under investigation. Nonetheless, we will bring that news to you as soon as it becomes available.

Update: This news is no longer chatter. The company is now under investigation by the UK CMA. The agency said that it is investigating various issues surrounding the UK pharmaceutical industry and that Concordia International is indeed part of the investigation.

What We Can Expect To See Ahead

Moving forward, I’m not quite sure what to expect. Ultimately, Twitter chatter can prove to be just that, chatter. However, if an investigation is taking place, this thing could get very ugly, very quickly. So, keep your eyes peeled with regard to CXRX as whichever direction this heads, it’s going to be an interesting ride.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again!

Do you want real time, actionable news delivered directly to your inbox? Join the CNA Finance mailing list and we’ll do just that! (Free for a limited time)

Subscribe Today!

* indicates required



[Image Courtesy of Pixabay]

Thought Leader Discussions

Josh Disbrow head shot1 (1)

0 1412
Aytu Bioscience Inc (OTCMKTS: AYTU) Recently, the CNA Finance team had an opportunity to speak with Josh Disbrow, CEO of Aytu Bioscience. Josh Disbrow has...